Activity of Wedelia calendulacea Less. in post-menopausal osteoporosis

S. Annie, R.G. Prabhu, S. Malini

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Wedelia calendulacea Less., a perennial herb containing isoflavanoids, is used in liver disorders, uterine hemorrhage and menorrhagia. Osteoporosis in women occurs mainly due to estrogen deficiency following menopause. Studies indicate that isoflavones are estrogenic enough to promote bone formation. Our study was aimed to investigate the antiosteoporotic effect of the ethanol extract of W. calendulacea in the ovariectomized rat model of osteoporosis, at two different dose levels of 500 and 750 mg/kg/body wt. day. The findings, assessed on the basis of biomechanical and biochemical parameters, showed that the ethanol extract of the plant had a definite protective effect. This was further supported by the histopathological studies. Phytochemical investigation revealed the presence of isoflavones and wedelolactone, which are known to act as phytoestrogens and may be responsible for the antiosteoporotic activity. © 2005 Elsevier GmbH. All rights reserved.
Original languageEnglish
Pages (from-to)43-48
Number of pages6
JournalPhytomedicine
Volume13
Issue number1-2
DOIs
Publication statusPublished - 2006
Externally publishedYes

Fingerprint

Wedelia
Postmenopausal Osteoporosis
Isoflavones
Osteoporosis
Ethanol
Menorrhagia
Phytoestrogens
Uterine Hemorrhage
Plant Extracts
Phytochemicals
Menopause
Osteogenesis
Estrogens
Liver

Cite this

Annie, S. ; Prabhu, R.G. ; Malini, S. / Activity of Wedelia calendulacea Less. in post-menopausal osteoporosis. In: Phytomedicine. 2006 ; Vol. 13, No. 1-2. pp. 43-48.
@article{acc4585e807041079fb8cbec67f38b80,
title = "Activity of Wedelia calendulacea Less. in post-menopausal osteoporosis",
abstract = "Wedelia calendulacea Less., a perennial herb containing isoflavanoids, is used in liver disorders, uterine hemorrhage and menorrhagia. Osteoporosis in women occurs mainly due to estrogen deficiency following menopause. Studies indicate that isoflavones are estrogenic enough to promote bone formation. Our study was aimed to investigate the antiosteoporotic effect of the ethanol extract of W. calendulacea in the ovariectomized rat model of osteoporosis, at two different dose levels of 500 and 750 mg/kg/body wt. day. The findings, assessed on the basis of biomechanical and biochemical parameters, showed that the ethanol extract of the plant had a definite protective effect. This was further supported by the histopathological studies. Phytochemical investigation revealed the presence of isoflavones and wedelolactone, which are known to act as phytoestrogens and may be responsible for the antiosteoporotic activity. {\circledC} 2005 Elsevier GmbH. All rights reserved.",
author = "S. Annie and R.G. Prabhu and S. Malini",
note = "Cited By :27 Export Date: 10 November 2017 CODEN: PYTOE Correspondence Address: Annie, S.; Department of Pharmacognosy, College of Pharmaceutical Sciences, Manipal, India; email: annie.shirwaikar@cops.manipal.edu Chemicals/CAS: isoflavone, 574-12-9; wedelolactone, 524-12-9; Plant Extracts References: Adams, N.R., Phyto-oestrogens (1989) Toxicants of Plant Origin, pp. 23-51. , P. Cheeke CRC Press Boca Raton, FL; Agnusdei, D., Zacchei, F., Bigazzi, S., Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis (1989) Drugs Exp. Clin. Res., 15 (2), pp. 97-104; (1964) The Wealth of India - Raw Materials, , Anonymous CSIR New Delhi; Bahram, H.A., Lee, A., Bruce, W.H., Dietary soybean prevents bone loss in a ovariectomized rat model of osteoporosis (1996) J. Nutr., 126, pp. 161-167; Bennet, A.E., Wahner, H.W., Riggs, B.L., Soya- a dietary source of the non steroidal estrogen equal in man and animals (1984) J. Endocrinol., 102, pp. 49-56; Benvenuti, S., Tanini, A., Masi, L., Effects of ipriflavone and its metabolites on clonal osteoblastic cell line (1991) J. Bone Miner. Res., 6, pp. 987-996; Blair, H.C., Action of genistein and other tyrosine kinase inhibitor in preventing osteoporosis (1996) Second International Symposium on the Role of Soya in Preventing and Treating Chronic Disease, , Brussels, Belgium 15-18 September; Canalis, H., McCarthy, T., Centrella, M., Growth factors and the regulation on bone remodelling (1988) J. Clin. Invest., 81, pp. 277-281; Fanti, P., Monier-Faugee, M.C., Geng, Z., The phytoestrogen genistein reduces bone loss in short term ovariectomized rats (1998) Osteoporosis Int., 8, p. 274; Genant, H.K., Baylink, D.J., Gallagher, J.C., Estrogens in the prevention of osteoporosis in post menopausal women (1989) Am. J. Obstet. Gynecol., 161, pp. 1842-1846; Gruber, H.E., Ivey, J.L., Baylink, D.L., Mathews, M., Nelp, W.B., Sisom, K., Chestnut, C.H., Long term calcitonin therapy in postmenopausal Osteoporosis (1984) Metabolism, 33, pp. 295-303; (1998) Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis, , WHO Geneva; Harborne, J.B., (1984) Phytochemical Methods, , second ed. Chapman and Hill London; Kokate, C.K., (1991) Practical Pharmacognosy, Third Ed., pp. 107-121. , Vallabh Prakashan; Marcus, R., Introduction: Organizational and functional aspects of skeletal health (1994) Osteoporosis, , J.A. Kanis Blackwell Science, Ltd. Oxford, England; Meryl, S.L., (1997) Metabolic Bone Diseases in Text Book of Rheumatology, pp. 1563-1572. , Harris. Kelley Sludge. Ruddy fifth ed. WB Saunders Co. London; Mitra, S.K., Venkataranganna, M.V., Venkatesha Udupa, U., The beneficial effect of OST-6 (OsteoCare), a herbomineral formulation in experimental osteoporosis (2001) Phytomedicine, 8 (3), pp. 195-201; Ogey, A., Bayraktar, F., Sevin, G., A comparative study of Raloxifen and estrogen on bone strength and cholesterol levels in ovariectomized rats (2001) Endocrine Abs., 3, p. 10; Peng, Z., Tuukkanen, J., Zhang, H., The mechanical strength of bone in different rat models of experimental osteoporosis (1994) Bone, 15, pp. 523-532; Prabha Shankar, B., Osteoporosis- a silent epidemic (2002) Pharma. Times, 34, pp. 21-22; Rashmi, G.P., Malini, S., Shirwaikar, A., (2002) Pharmacognostical Phytochemical and Antiosteoporotic Activity of W. Calendulacea Less, , Manipal Academy of Higher Education, Karnataka, India (Dessertation) Manipal; Wagner, H., Fessler, B., In vitro 5-lipoxygenase ingibition by E. alba and the coumestan derivative wedelolactone from W. calendulacea (1986) Planta Medica, (5), pp. 374-377; Wronski, T.J., Dann, L.M., Scott, K.S., Cintron, M., Long term effects of ovariectomy and aging on the rat skeleton (1989) Calcif. Tissue Int., 45, pp. 360-366; Yamaguchi, M., Gao, Genistein inhibits bone loss (1998) Biochem. Pharmacol., 55, p. 71",
year = "2006",
doi = "10.1016/j.phymed.2004.01.011",
language = "English",
volume = "13",
pages = "43--48",
journal = "Phytomedicine",
issn = "0944-7113",
publisher = "Urban und Fischer Verlag Jena",
number = "1-2",

}

Activity of Wedelia calendulacea Less. in post-menopausal osteoporosis. / Annie, S.; Prabhu, R.G.; Malini, S.

In: Phytomedicine, Vol. 13, No. 1-2, 2006, p. 43-48.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Activity of Wedelia calendulacea Less. in post-menopausal osteoporosis

AU - Annie, S.

AU - Prabhu, R.G.

AU - Malini, S.

N1 - Cited By :27 Export Date: 10 November 2017 CODEN: PYTOE Correspondence Address: Annie, S.; Department of Pharmacognosy, College of Pharmaceutical Sciences, Manipal, India; email: annie.shirwaikar@cops.manipal.edu Chemicals/CAS: isoflavone, 574-12-9; wedelolactone, 524-12-9; Plant Extracts References: Adams, N.R., Phyto-oestrogens (1989) Toxicants of Plant Origin, pp. 23-51. , P. Cheeke CRC Press Boca Raton, FL; Agnusdei, D., Zacchei, F., Bigazzi, S., Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis (1989) Drugs Exp. Clin. Res., 15 (2), pp. 97-104; (1964) The Wealth of India - Raw Materials, , Anonymous CSIR New Delhi; Bahram, H.A., Lee, A., Bruce, W.H., Dietary soybean prevents bone loss in a ovariectomized rat model of osteoporosis (1996) J. Nutr., 126, pp. 161-167; Bennet, A.E., Wahner, H.W., Riggs, B.L., Soya- a dietary source of the non steroidal estrogen equal in man and animals (1984) J. Endocrinol., 102, pp. 49-56; Benvenuti, S., Tanini, A., Masi, L., Effects of ipriflavone and its metabolites on clonal osteoblastic cell line (1991) J. Bone Miner. Res., 6, pp. 987-996; Blair, H.C., Action of genistein and other tyrosine kinase inhibitor in preventing osteoporosis (1996) Second International Symposium on the Role of Soya in Preventing and Treating Chronic Disease, , Brussels, Belgium 15-18 September; Canalis, H., McCarthy, T., Centrella, M., Growth factors and the regulation on bone remodelling (1988) J. Clin. Invest., 81, pp. 277-281; Fanti, P., Monier-Faugee, M.C., Geng, Z., The phytoestrogen genistein reduces bone loss in short term ovariectomized rats (1998) Osteoporosis Int., 8, p. 274; Genant, H.K., Baylink, D.J., Gallagher, J.C., Estrogens in the prevention of osteoporosis in post menopausal women (1989) Am. J. Obstet. Gynecol., 161, pp. 1842-1846; Gruber, H.E., Ivey, J.L., Baylink, D.L., Mathews, M., Nelp, W.B., Sisom, K., Chestnut, C.H., Long term calcitonin therapy in postmenopausal Osteoporosis (1984) Metabolism, 33, pp. 295-303; (1998) Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis, , WHO Geneva; Harborne, J.B., (1984) Phytochemical Methods, , second ed. Chapman and Hill London; Kokate, C.K., (1991) Practical Pharmacognosy, Third Ed., pp. 107-121. , Vallabh Prakashan; Marcus, R., Introduction: Organizational and functional aspects of skeletal health (1994) Osteoporosis, , J.A. Kanis Blackwell Science, Ltd. Oxford, England; Meryl, S.L., (1997) Metabolic Bone Diseases in Text Book of Rheumatology, pp. 1563-1572. , Harris. Kelley Sludge. Ruddy fifth ed. WB Saunders Co. London; Mitra, S.K., Venkataranganna, M.V., Venkatesha Udupa, U., The beneficial effect of OST-6 (OsteoCare), a herbomineral formulation in experimental osteoporosis (2001) Phytomedicine, 8 (3), pp. 195-201; Ogey, A., Bayraktar, F., Sevin, G., A comparative study of Raloxifen and estrogen on bone strength and cholesterol levels in ovariectomized rats (2001) Endocrine Abs., 3, p. 10; Peng, Z., Tuukkanen, J., Zhang, H., The mechanical strength of bone in different rat models of experimental osteoporosis (1994) Bone, 15, pp. 523-532; Prabha Shankar, B., Osteoporosis- a silent epidemic (2002) Pharma. Times, 34, pp. 21-22; Rashmi, G.P., Malini, S., Shirwaikar, A., (2002) Pharmacognostical Phytochemical and Antiosteoporotic Activity of W. Calendulacea Less, , Manipal Academy of Higher Education, Karnataka, India (Dessertation) Manipal; Wagner, H., Fessler, B., In vitro 5-lipoxygenase ingibition by E. alba and the coumestan derivative wedelolactone from W. calendulacea (1986) Planta Medica, (5), pp. 374-377; Wronski, T.J., Dann, L.M., Scott, K.S., Cintron, M., Long term effects of ovariectomy and aging on the rat skeleton (1989) Calcif. Tissue Int., 45, pp. 360-366; Yamaguchi, M., Gao, Genistein inhibits bone loss (1998) Biochem. Pharmacol., 55, p. 71

PY - 2006

Y1 - 2006

N2 - Wedelia calendulacea Less., a perennial herb containing isoflavanoids, is used in liver disorders, uterine hemorrhage and menorrhagia. Osteoporosis in women occurs mainly due to estrogen deficiency following menopause. Studies indicate that isoflavones are estrogenic enough to promote bone formation. Our study was aimed to investigate the antiosteoporotic effect of the ethanol extract of W. calendulacea in the ovariectomized rat model of osteoporosis, at two different dose levels of 500 and 750 mg/kg/body wt. day. The findings, assessed on the basis of biomechanical and biochemical parameters, showed that the ethanol extract of the plant had a definite protective effect. This was further supported by the histopathological studies. Phytochemical investigation revealed the presence of isoflavones and wedelolactone, which are known to act as phytoestrogens and may be responsible for the antiosteoporotic activity. © 2005 Elsevier GmbH. All rights reserved.

AB - Wedelia calendulacea Less., a perennial herb containing isoflavanoids, is used in liver disorders, uterine hemorrhage and menorrhagia. Osteoporosis in women occurs mainly due to estrogen deficiency following menopause. Studies indicate that isoflavones are estrogenic enough to promote bone formation. Our study was aimed to investigate the antiosteoporotic effect of the ethanol extract of W. calendulacea in the ovariectomized rat model of osteoporosis, at two different dose levels of 500 and 750 mg/kg/body wt. day. The findings, assessed on the basis of biomechanical and biochemical parameters, showed that the ethanol extract of the plant had a definite protective effect. This was further supported by the histopathological studies. Phytochemical investigation revealed the presence of isoflavones and wedelolactone, which are known to act as phytoestrogens and may be responsible for the antiosteoporotic activity. © 2005 Elsevier GmbH. All rights reserved.

U2 - 10.1016/j.phymed.2004.01.011

DO - 10.1016/j.phymed.2004.01.011

M3 - Article

VL - 13

SP - 43

EP - 48

JO - Phytomedicine

JF - Phytomedicine

SN - 0944-7113

IS - 1-2

ER -